In the latest trading session, 1.75 million Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares changed hands as the company’s beta touched 1.30. With the company’s most recent per share price at $10.06 changed hands at -$1.53 or -13.16% at last look, the market valuation stands at $969.86M. AVDL’s current price is a discount, trading about -89.76% off its 52-week high of $19.09. The share price had its 52-week low at $10.41, which suggests the last value was -3.48% down since then. When we look at Avadel Pharmaceuticals plc’s average trading volume, we note the 10-day average is 1.17 million shares, with the 3-month average coming to 1.13 million.
Analysts gave the Avadel Pharmaceuticals plc (AVDL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AVDL as a Hold, 8 felt it is a Buy and 0 rated the stock as Underweight. Avadel Pharmaceuticals plc’s EPS for the current quarter is expected to be -0.04.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
Instantly AVDL was in red as seen in intraday trades today. With action -10.29%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -28.72%, with the 5-day performance at -10.29% in the red. However, in the 30-day time frame, Avadel Pharmaceuticals plc (NASDAQ:AVDL) is -33.12% down. Looking at the short shares, we see there were 8.81 million shares sold at short interest cover period of 6.21 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 16.17% from its recent market value. According to analyst projections, AVDL’s forecast low is 9 with 30 as the target high. To hit the forecast high, the stock’s price needs a -198.21% plunge from its current level, while the stock would need to tank 10.54% for it to hit the projected low.
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
Data shows that the Avadel Pharmaceuticals plc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -34.90% over the past 6 months, a 76.00% in annual growth rate that is considerably higher than the industry average of 16.60%. Year-over-year growth is forecast to reach 512.99% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 52.7M. 6 analysts are of the opinion that Avadel Pharmaceuticals plc’s revenue for the current quarter will be 58.71M. The company’s revenue for the corresponding quarters a year ago was 19.45M and 27.18M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 170.89%. The estimates for the next quarter sales put growth at 116.02%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.78%. The 2024 estimates are for Avadel Pharmaceuticals plc earnings to increase by 76.06%, but the outlook for the next 5-year period is at 15.00% per year.
AVDL Dividends
Avadel Pharmaceuticals plc is expected to release its next quarterly earnings report in January.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.77% of Avadel Pharmaceuticals plc shares while 80.12% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.13%. There are 80.12% institutions holding the Avadel Pharmaceuticals plc stock share, with VIVO CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 4.332% of the shares, roughly 3.97 million AVDL shares worth $55.85 million.
TRI LOCUM PARTNERS LP holds the second largest percentage of outstanding shares, with 1.2973% or 1.19 million shares worth $16.72 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and Janus Henderson Global Life Sciences Fund. With 2.98 shares estimated at $30.0 million under it, the former controlled 3.10% of total outstanding shares. On the other hand, Janus Henderson Global Life Sciences Fund held about 3.02% of the shares, roughly 2.91 shares worth around $29.24 million.
